Lung Cancer

Benjamin Levy, MD, reviews clinical data on T-DXd in HER2 mutated advanced NSCLC and their practical implications.

Edgardo Santos, MD, FACP, FCCP, analyzes the influence on clinical practice arising from the application of cemiplimab with chemotherapy in advanced non-small cell lung cancer (NSCLC) observed in the EMPOWER-Lung3 trial.

Edgardo Santos, MD, FACP, FCCP, provides expert insights into the latest data from the TROPION-Lung01 trial, emphasizing the potential implications of this information for treating patients with non-actionable biomarkers in NSCLC.

Treatment with THIO followed by cemiplimab-rwlc led to a high DCR regardless of dose level in patients with pretreated non–small cell lung cancer.

Benjamin Levy, MD, discusses the role of molecular testing in patients with advanced NSCLC.

Lyudmila A. Bazhenova, MD, discusses key factors in the management of unresectable non–small cell lung cancer, emphasizing the importance of understanding and performing biomarker testing in this population.

A PMA application seeking approval of TTFields to standard therapies in patients with non­–small cell lung cancer has been accepted for filing by the FDA.

Jason Porter, MD, discusses the implications of adjuvant EGFR TKI use, the importance of the potential FDA approval of osimertinib in EGFR+ NSCLC, & more.

The European Commission granted marketing authorization for SC atezolizumab co-formulated with Enhanze for all approved indications of IV atezolizumab.

The initiation of immunotherapy at the end of life among patients with advanced cancers is increasing over time.

Treatment with JBI-802, the first-in-class CoREST inhibitor with dual LSD1 and HDAC6 activity was shown to be safe and active.

An MAA seeking the approval of lazertinib plus amivantamab in the first-line treatment of adult patients with EGFR+ NSCLC has been submitted to the EMA.

The Florez Lab at Dana-Farber Cancer Institute is launching the innovative International Pregnancy and Lung Cancer Registry.

Edgardo Santos, MD, FACP, FCCP, analyzes the recent developments in the DESTINY-Lung01 and DESTINY-Lung02 trials, specifically focusing on HER2+ NSCLC patients with brain metastases and exploring the potential impact on clinical practice.

Edgardo Santos, MD, FACP, FCCP, provides insights into the innovative Beamion Lung 1 trial, focused on assessing the safety and tolerability of zongertinib (BI 1810631) in patients with advanced, previously treated HER2+ non-small cell lung cancer (NSCLC).

The European Commission has granted conditional marketing authorization to adagrasib for patients with KRAS G12C+ advanced non–small cell lung cancer.

Cobolimab plus dostarlimab-gxly showed activity and acceptable safety across all dose levels assessed in patients with non–small cell lung cancer.

Heather Wakelee, MD, discusses the importance of balancing toxicities with efficacy as the non–small cell lung cancer treatment paradigm shifts.

Anne Chiang, MD, PhD, discusses treating patients with advanced non–small cell lung cancer without driver mutations.

Lenvatinib plus pembrolizumab, pemetrexed, and carboplatin or cisplatin did not improve treatment outcomes compared with placebo plus pembrolizumab, pemetrexed, and carboplatin or cisplatin when given as first-line therapy in patients with stage IV nonsquamous non–small cell lung cancer.

Eduardo Santos, MD, FACP, FCCP, highlights the most impactful and treatment-changing data updates for NSCLC in 2023, and provides perspective on how these finding may shape the future direction of care.

Eduardo Santos, MD, FACP, FCCP, discusses recent advances in dual immunotherapy approaches for NSCLC, highlighting data from the CheckMate 9LA study.

Lenvatinib plus pembrolizumab did not provide a survival advantage vs standard-of-care docetaxel in patients with advanced-stage non–small cell lung cancer who experienced disease progression following prior exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

The safety and efficacy data observed with the administration of 5 or more cycles of induction platinum/etoposide and concurrent durvalumab in patients with extensive-stage small cell lung cancer enrolled in the phase 3b LUMINANCE study aligned with outcomes reported in the phase 3 CASPIAN trial.

Adjuvant treatment with pembrolizumab continued to induce a disease-free survival benefit vs placebo in patients with resected early-stage NSCLC, according to findings from the phase 3 PEARLS/KEYNOTE-091 trial.